Alessandro Iannaccone is a distinguished professional in the field of medicine, currently serving as the Global Medical Lead for Cell and Gene Therapy in the Biopharma and Ophthalmology Division at Astellas Pharma since May 2023 and as a Professor at the University of North Carolina at Chapel Hill from April 2024. With extensive consulting experience, Iannaccone has been providing expert opinions to investors on treatment approaches for retinal dystrophies and degenerations for multiple organizations, including Guidepoint, GLG, ClearView Healthcare Partners, Advance Medical, Inc., and IQVIA since 2015. Additionally, Iannaccone has held advisory roles at Eluminex Biosciences Limited and Alia Therapeutics, contributing to the development of gene therapy approaches for inherited retinal diseases. Iannaccone's academic background includes degrees from prestigious institutions such as Sapienza Università di Roma and the University of Tennessee Health Science Center, with expertise in Epidemiology and Biostatistics.
This person is not in any teams
This person is not in any offices